Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Stat-Diagnostica Appoints Vaillant as Chairman of the Board


Spanish medical diagnostics firm Stat-Diagnostica has appointed Gerard Vaillant as chairman of its board of directors.

Vaillant has held of number of senior executive positions within Johnson & Johnson, including managing director of Ortho Clinical Diagnostics France; vice president of J&J International; worldwide president, LifeScan, a J&J company; and group chairman, diagnostics worldwide. He was also a member of J&J’s Medical Devices and Diagnostic Group Operating Committee until retiring in 2004. After his retirement from J&J, he remained as a board member of both Luminex and Vivacta.

In addition to his current position with Stat-Diagnostica, Vaillant currently serves as chairman of the board of SafeOrthopaedics and PathoQuest; a board member of Tecan; and a venture partner at KLS Partners.

Stat-Diagnostic said that Vaillant "brings expert industry perspective and guidance" to the company as it prepares for the successive European and US launches of its DiagCORE near-patient testing platform (PCR Insider, 5/16/2013)

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.